Notably, the PCD by PL-RB was approximately 30% higher than that of the non-cross-linked RB or RB-RAH at the same dosage, which indicated that linking both R and B together for the anti-NHL therapy is necessary. The gene discussed is RAB34; the disease is non-Hodgkin lymphoma.